Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2011

01-05-2011 | Clinical trial

Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study

Authors: George Pentheroudakis, Anna Batistatou, Konstantine T. Kalogeras, Ralf Kronenwett, Ralph M. Wirtz, Evangelos Bournakis, Anastasia G. Eleftheraki, Dimitrios Pectasides, Mattheos Bobos, Irini Papaspirou, Sevasti Kamina, Helen Gogas, Angelos K. Koutras, Nicholas Pavlidis, George Fountzilas

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Login to get access

Abstract

We evaluated the prognostic and predictive utility of β-tubulin isotype III (TUBB3) tumour gene transcription in early breast cancer patients enrolled in a randomised study. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was applied for assessment of TUBB3, ER, PgR, HER2 and MAPT messenger RNA and immunohistochemistry (IHC) for protein expression in 314 patients enrolled in trial HE10/97, evaluating epirubicin–alkylator adjuvant chemotherapy with or without paclitaxel. High TUBB3 mRNA status was associated with advanced T stage, high histological grade, low mRNA and protein levels of ER, PgR and MAPT, and high levels of HER2 (p < 0.001). At a median follow-up of 98 months, multivariate analysis showed high TUBB3 mRNA status to have prognostic significance for DFS (HR = 1.83, 95% CI 1.25–2.68, p = 0.002) and OS (HR = 1.71, 95% CI 1.03–2.83, p = 0.038), along with the number of involved axillary nodes, PgR mRNA status and tumour grade. TUBB3 mRNA levels did not predict benefit from inclusion of paclitaxel in adjuvant chemotherapy (test for interaction p = 0.96 for OS, p = 0.46 for DFS). Transcriptional activity of β-tubulin isotype III in early breast cancer is an adverse prognostic factor, though not a predictive one for taxane efficacy.
Appendix
Available only for authorised users
Literature
1.
EBCTC Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials. Lancet 365:1687–1717CrossRef
2.
Trudeau M, Charbonneau F, Gelmon K et al (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886–898PubMedCrossRef
3.
Bedard P, Leo A, Piccart-Gebhart M (2010) Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 7:22–36PubMedCrossRef
4.
Bhat KMR, Setaluri V (2007) Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 13:2849–2854PubMedCrossRef
5.
Mollinedo F, Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8:413–450PubMedCrossRef
6.
Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10:194–204PubMedCrossRef
7.
Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E et al (2005) Postoperative dose-dense sequential chemotherapy with epirubicin, followed byCMFwith or without paclitaxel, in patients with high-risk operable breast cancer: a randomised phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 16:1762–1771PubMedCrossRef
8.
Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S, Schaefer K-L (2009) RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 55:1719–1727PubMedCrossRef
9.
Mueller BM, Kronenwett R, Hennig G, Euting H, Weber K et al (2011) Quantitative determination of estrogen receptor, progesterone receptor and HER2 mRNA in formalin-fixed paraffin-embedded tissue—a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol 20:1–10CrossRef
10.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795PubMedCrossRef
11.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18–43PubMed
12.
Pusztai L, Jeong J-H, Gong Y, Ross JS, Kim C, Paik S, et al (2009) Evaluation of microtubule-associated protein-tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol 27:4287–4292PubMedCrossRef
13.
Pentheroudakis G, Kalogeras K, Wirtz R, Grimani I, Zografos G, Gogas H et al (2009) Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat 116:131–143PubMedCrossRef
14.
Hudis TL (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127–2132PubMedCrossRef
15.
McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067–9072PubMedCrossRef
16.
Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265PubMedCrossRef
17.
Cleveland DW, Sullivan KF (1985) Molecular biology and genetics of tubulin. Annu Rev Biochem 54:331–365PubMedCrossRef
18.
Lopata MA, Cleveland DW (1987) In vivo microtubules are copolymers of available h-tubulin isotypes: localization of each of six vertebrate h-tubulin isotypes using polyclonal antibodies elicited by synthetic peptide antigens. J Cell Biol 105:1707–1720PubMedCrossRef
19.
Cicchillitti L, Penci R, Di Michele M, Fillipetti F, Rotilio D, Benedetta Donati M et al (2008) Proteomic characterisation of cytoskeletal and mitochondrial class III b-tubulin. Mol Cancer Ther 7:2070–2079PubMedCrossRef
20.
Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Mechanisms of taxol resistance related to microtubules. Oncogene 22:7280–7295PubMedCrossRef
21.
Mozzetti S, Ferlini C, Concolino P, Fillippetti F, Raspaglio G, Prislei S et al (2005) Class III b-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11:298–305PubMed
22.
Hasegawa S, Miyoshi Y, Egawa C et al (2003) Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 9:2992–2997PubMed
23.
Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M (2006) The beta/beta III tubulin isoforms and their complexes with antimitotic agents: Docking and molecular dynamics studies. FEBS J 273:3301–3310PubMedCrossRef
24.
Seve P, Dumontet C (2008) Is class III b-tubulin a predictive factor in patients receiving tubulin-binding agents? Oncology 9:168–175PubMed
25.
Seve P, Lai R, Ding K et al (2007) Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer. Analysis of NCIC BR.10. Clin Cancer Res 13:994–999PubMedCrossRef
26.
Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M et al (2010) BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 16:3988–3997PubMedCrossRef
27.
Dennis K, Ulttenbogaard M, Chiaramello A, Moody SA (2002) Cloning and characterisation of 5-flanking region of the rat neuron-specific class III beta-tubulin gene. Gene 294:269–277PubMedCrossRef
28.
Raspaglio G, Filipetti F, Prislei S et al (2008) Hypoxia induces Class III beta-tubulin gene expression by HIF1a binding to its 3-flanking region. Gene 409:100–108PubMedCrossRef
29.
Gan PP, Pasquier E, Kavallaris M (2007) Class III b-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67:9356–9363PubMedCrossRef
30.
Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA et al (2004) Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64(23):8541–8549PubMedCrossRef
31.
Kaur GP, Reddy DE, Zimonjic DB, de Riel JK, Athwal RS (2005) Functional identification of a BAC clone from 16q24 carrying a senescence gene SEN16 for breast cancer cells. Oncogene 24(1):47–54PubMedCrossRef
32.
Chin SF, Wang Y, Thorne NP, Teschendorff AE, Pinder SE, Vias M et al (2007) Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 26(13):1959–1970PubMedCrossRef
33.
Mongroo PS, Rustgi AK (2010) The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther 10(3):219–222PubMedCrossRef
34.
Goldstein NS, Ferkowicz M, Odish E et al (2003) Minimum formalin fixation time for consistent estrogen receptor immunocytochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86–92PubMedCrossRef
35.
Rhodes A (2003) Quality assurance in immunohistochemistry. Am J Surg Pathol 27:1284–1285PubMed
36.
Morris KV (2008) RNA-mediated transcriptional gene silencing in human cells. Curr Top Microbiol Immunol 320:211–224PubMedCrossRef
37.
Ravo M, Mutarelli M, Ferraro L, Grober OM, Paris O et al (2008) Quantitative expression profiling of highly degraded RNA from formalin-fixed paraffin-embedded breast tumour biopsies by oligonucleotide microarrays. Lab Invest 88:430–440PubMedCrossRef
38.
39.
Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. PNAS 102:8315–8320PubMedCrossRef
40.
Andre F, Hatzis C, Anderson K, Sotiriou S, Mazouni C et al (2007) Microtubule-associated protein tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen-receptor positive breast cancer. Clin Cancer Res 13:2061–2067PubMedCrossRef
Metadata
Title
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study
Authors
George Pentheroudakis
Anna Batistatou
Konstantine T. Kalogeras
Ralf Kronenwett
Ralph M. Wirtz
Evangelos Bournakis
Anastasia G. Eleftheraki
Dimitrios Pectasides
Mattheos Bobos
Irini Papaspirou
Sevasti Kamina
Helen Gogas
Angelos K. Koutras
Nicholas Pavlidis
George Fountzilas
Publication date
01-05-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1427-0

Other articles of this Issue 1/2011

Breast Cancer Research and Treatment 1/2011 Go to the issue

Clinical trial

The effect of various vitamin D supplementation regimens in breast cancer patients

Epidemiology

The non-breast-cancer death rate among breast cancer patients

Review

Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis

Preclinical study

Identification of immunodominant HLA-B7-restricted CD8+ cytotoxic T cell epitopes derived from mammaglobin-A expressed on human breast cancers

Epidemiology

Sentinel node micrometastases in breast cancer do not affect prognosis: a population-based study

Epidemiology

Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤40 years
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits